

**The Italian-Israeli Conference on Biosimilars:
“Between Innovation and Optimization: Challenges and Opportunities in biosimilars
for the Israeli and Italian Biopharma Industry”
Wednesday, June 12th 2013 David Intercontinental, Hall B
In the frameworks of “Biomed 2013”**

9:00 - 9:15	Registration and Breakfast
9.15 - 9.45	<p>Greetings H.E. Ambassador Francesco Maria Talo Ambassador of Italy to Israel TBD ISS TBD Israeli Ministry of health</p>
9.45 -10.05	<p><u>Introduction to the Biotecnologies in Italy</u> Paolo Daniele Siviero Coordinatore area strategie e politiche del farmaco; Direttore Ufficio Centro Studi Aifa Aifa</p> <p>Daniela Jabes Assobiotec <i>“The Italian Biotechnology scenario: evolution toward innovative medicine”</i></p>
10.05 - 11.20	<p><u>1st Session: Research and Process</u> D. Melamed CEO Insight Biopharmaceutica</p> <p>G. Tonon General Manager; Bio-Ker-Multimedica Group. <i>“Biosimilar and biobetter: preparation and development”</i></p> <p>Elisha Nathan CEO Protalix</p> <p>Giorgio Mosconi MD Former Pierrel Chief Strategic Officer <i>“Pierrel Research and Manufacturing: excellence in services for biopharmaceuticals”</i></p> <p>Ruth Ben Yakar CEO Procognia <i>“Informed development of quality biosimilars”</i></p>
11.20- 11.40	Coffee Break
11.40 - 12.30	<p><u>2nd Session: Regulatory and policy</u></p> <p>Michele Uda Assogenerici <i>“Best practices around Europe supporting uptake of biosimilars: shaping the future, Italy experience”</i></p> <p>Claudio Panzarella Business Scout Director Menarini</p> <p>TBD Regulation In Israel (IATI)</p>
12.30 -12.45	<p>Examples of Cooperation Italian-Israeli in this sector (Genzyme Israele) Zeev Zelig VP Genzyme Israel</p>
13.30 - 13.45	Final Remarks and Lunch